Clinical Trials · NCT06260722
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Eli Lilly and Company
- Enrollment
- 1,250
- Start date
- Feb 2024
- Locations
- 77 sites, 5 countries
- Primary endpoint
- Change from Baseline in Hemoglobin A1c (HbA1c) (%)